HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101
[Taipei, Shanghai, San Francisco | May 28, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company’s core technology is its proprietary FBDB™ platform, which integrates multiple immune-modulating mechanisms into a single molecule and supports the development of multi-target, multifunctional biologic therapies.
Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, said platform technology is an important foundation for building long-term biotechnology value. By supporting the generation of multiple research and development assets over time, platform capabilities may help diversify risks associated with single-asset drug development while strengthening the long-term potential of the Company’s pipeline.
HanchorBio has built a pipeline of clinical and preclinical candidates, including HCB101, HCB301, HCB303, and HCB206. The Company’s lead program, HCB101, is a CD47-targeting anti-cancer drug candidate designed through precision protein engineering to block tumor immune-evasion signals and restore macrophage-mediated tumor phagocytosis. HCB101 is currently being advanced in Phase 2a clinical development in combination with ramucirumab and paclitaxel for gastric cancer, while also being evaluated in additional indications, including head and neck cancer, colorectal cancer, and triple-negative breast cancer.
HCB301, a trifunctional fusion protein designed to address three key tumor immune-escape mechanisms, has entered Phase 1 clinical trials in the United States, mainland China, and Taiwan. HCB303 is a next-generation multi-target immunotherapy candidate currently under clinical development planning, while HCB206, the Company’s dual-mechanism autoimmune disease program, is viewed as an important potential driver of future pipeline value.
Dr. Liu noted that, in biotechnology licensing and partnership discussions, early clinical data supported by proof-of-concept findings are often a key factor in attracting global pharmaceutical partners. Such data may provide initial evidence of safety, clinical activity, and potential differentiation in patients.
HCB101 has shown encouraging early clinical activity in ongoing multinational Phase 1b/2a studies. In a mid-dose cohort evaluating HCB101 in combination with standard therapy for second-line gastric cancer, the regimen demonstrated an objective response rate (ORR) of 80%, with favorable safety and tumor reduction observations. Preliminary data from gastric cancer and first-line triple-negative breast cancer cohorts have also shown encouraging response and disease control signals. If subsequent Phase 2a proof-of-concept data across multiple indications remain supportive, the Company believes HCB101 may further positioned for global partnering discussions.
HanchorBio is pursuing a multi-indication clinical development strategy for HCB101, designed to support flexible business development opportunities, including licensing, co-development, and potential strategic transactions. Following its licensing agreement last year with Henlius for the development and commercialization rights to HCB101 in mainland China and certain territories, valued at up to US$202 million, HanchorBio has continued to advance discussions with multiple global pharmaceutical companies. The Company is currently engaged in ongoing partnering discussions for global and regional rights to HCB101 outside previously licensed territories.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.
漢康將於5月29日創新板掛牌 HCB101臨床進展帶動國際合作布局
專注創新藥物開發的漢康-KY（股票代碼：7827）將於明（29）日以每股 120 元承銷價正式掛牌創新板上市，為台灣生技資本市場再添具備國際授權實力的關鍵生力軍。
漢康-KY致力於開發突破性免疫療法，鎖定龐大的癌症與自體免疫疾病兩大剛性需求市場。公司核心競爭力源自獨家研發的FBDB多功能融合蛋白平台。該平台能透過單一分子整合多個免疫調控機制，有效突破傳統生物藥的結構與功能限制，具備支持多靶點與多功能生物藥開發的強大推進力。
漢康-KY董事長劉世高表示，對生技公司而言，平台型技術（Platform Technology）代表其具備持續產出多元研發資產的「造血功能」，不僅能大幅分散單一新藥研發風險，更為公司奠定長線產品線的紮實價值基石。
目前漢康-KY已建構具備高商業價值的候選新藥組合，包括 HCB101、HCB301、HCB303 與 HCB206等核心產品線。其中研發進度最快的核心產品 HCB101，定位為靶向CD47的「同類最佳（Best-in-Class）」抗癌藥物，透過精密蛋白工程阻斷癌細胞的偽裝信號，重啟人體巨噬細胞吞噬腫瘤的功能。目前臨床設計以HCB101為基礎治療骨幹，聯合雷莫蘆單抗及化療藥紫杉醇，全力推進二a期臨床試驗，並同步拓展至頭頸癌、結直腸癌、三陰性乳癌等多項高適應症市場。
此外，同時針對腫瘤三條主要免疫逃脫機制設計的三功能融合蛋白藥物HCB301，目前已於美國、中國大陸與台灣同步展開一期臨床試驗；而多靶點下一代免疫療法候選藥物 HCB303 目前正處於臨床開發規劃階段；公司旗下具雙重作用機制的自體免疫疾病項目 HCB206，則被視為未來推動產品管線價值提升的重要潛在動能。
劉世高指出，在生技醫藥的對外授權策略中，臨床早期數據若具備概念驗證（POC）支撐，代表該藥物已在人體試驗中初步證明其安全性與顯著療效，這正是吸引國際大藥廠（Big Pharma）承接、獲取高額前期授權金與里程碑金的最關鍵指標。
目前HCB101在多國進行的一b/二a期臨床試驗中，已實質展現極高的國際授權價值。在二線胃癌聯合標準治療方案的中劑量組客觀緩解率（ORR）高達80%，展現極佳安全性與腫瘤縮小效果；同時，胃癌及三陰性乳癌的初步數據亦顯示出令人鼓舞的腫瘤反應與疾病控制訊號。若後續多適應症的二a期臨床POC數據能延續，未來可望HCB101進一步推動全球合作洽談
劉世高強調，漢康-KY採取「一藥治多癌」的多重臨床路徑策略，為公司創造技術授權、共同開發或具潛在併購價值等多種靈活的商業獲利模式。繼去年以高達2.02億美元（約當新台幣65億元）的授權總額，將HCB101在中國大陸與特定地區的開發與銷售權獨家授予復宏漢霖，成功完成首階段價值變現後，公司的國際商務談判進展已顯著加速。目前正持續與多家全球前50大跨國藥廠積極洽談全球及其他區域授權，公司內部對今年內再度達成HCB101新的國際市場授權抱持高度信心，掛牌上市後的營運表現與跨國授權進展值得高度期待。